Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
US11077143B2 · kind B2 · utility
6Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2019 |
| Grant date | Aug 3, 2021 |
| Priority date | — |
| Expiry date | Aug 1, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/03
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.